Mechanistic Research and Therapeutic Prospects of Alternative Splicing in Neurodegenerative Diseases.
This review summarizes how alternative splicing contributes to neurodegenerative diseases, highlights dysregulated splicing of SNCA and PARK2 in Parkinson's disease, and surveys emerging splicing-based therapies and biomarkers.
What the AI sees
This review summarizes how alternative splicing contributes to neurodegenerative diseases, highlights dysregulated splicing of SNCA and PARK2 in Parkinson's disease, and surveys emerging splicing-based therapies and biomarkers.
Research significance
By cataloging disease-relevant splicing events and therapeutic approaches (e.g., antisense oligonucleotides, RBP modulation), the paper points to actionable targets and biomarker strategies that can inform Parkinson's translational research.
Source abstract
One essential post-transcriptional regulatory mechanism that increases protein diversity in eukaryotes is alternative splicing. This process is crucial for maintaining nervous system function and is highly active in neurons. Dysregulation of alternative splicing is a common pathogenic factor in many neurodegenerative diseases. For example, splicing variants of tau protein and amyloid precursor protein are implicated in Alzheimer's disease; aberrant splicing of α-synuclein (SNCA) and upregulation of specific transcript variants of the Parkin (PARK2) gene occurs in Parkinson's disease; and aberrant splicing of Stathmin-2 (STMN2) pre-mRNA leads to the loss of axonal maintenance proteins in amyotrophic lateral sclerosis and frontotemporal dementia. This process is precisely regulated by trans-acting factors, a class of RBPs that specifically recognize and bind to cis-acting elements on precursor mRNA (pre-mRNA). These factors are primarily categorized into two major groups: serine/arginine-rich (SR) proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs). Although hnRNPs and SR proteins have been shown to regulate neuronal alternative splicing, their complex regulatory networks and associated disease mechanisms remain incompletely understood, hindering the development of targeted therapies. This review summarizes the molecular mechanisms of alternative splicing and its regulatory features in neurodegenerative diseases. It also summarizes recent advances in splicing-based therapies and biomarkers, providing insights into disease mechanisms and therapeutic development.